EUVIMEDEUVIMED entdecken
Crossref

Serum levels of autotaxin reveal its role as a novel biomarker of migraine

Alberto Ouro iD, Mónica Castro-Mosquera, Mariña Rodríguez-Arrizabalaga, Manuel Debasa-Mouce, Daniel Romaus-Sanjurjo, Marta Aramburu-Nuñez, Ramón Iglesias-Rey, Josefina Casas, Isabel Lema, José Castillo, Rogelio Leira, Tomás Sobrino

Headache: The Journal of Head and Face Pain · 2025

DOI: 10.1111/head.14922 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, 2025. Verfasst von Alberto Ouro und 11 weiteren Autor:innen. Beteiligte Einrichtung: NeuroAging Group Laboratory (NEURAL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), …. Hauptthemen laut MEDLINE: Phosphoric Diester Hydrolases, Migraine Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Xunta de Galicia, Interreg, Instituto de Salud Carlos III (ISCIII).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Migraine is the most common neurological disorder and the second most disabling human condition. Autotaxin (ATX) is a plasma enzyme that leads to the formation of lysophosphatidic acid (LPA), which is involved in different functions involved in migraine, such as vascular tone control, inflammation, neuronal excitation, endothelial dysfunction, and neuropathic pain, among others. Most patients with migraine are females and, interestingly, ATX is physiologically higher in the serum of females compared to males.

Objective

As ATX may be a link between common mechanisms associated with migraine, we aimed to determine the potential role of ATX in migraine by studying its concentrations in serum between patients with episodic (EM) and chronic migraine (CM) compared to healthy controls, as well as the correlation of ATX with clinical outcomes, and other biomarkers described in migraine.

Methods

In this cross‐sectional study, healthy controls ( n = 62), and patients with EM ( n = 45), and CM ( n = 38) were studied. Clinical outcomes, such as migraine intensity as assessed on a visual analog scale (VAS), frequency of headaches (days/month), evolution time (months), and the duration of attacks (h) were investigated together with the serum biomarkers for inflammation (interleukin 6 [IL‐6] and IL‐10), trigeminovascular system activation (calcitonin gene‐related peptide [CGRP]), endothelial dysfunction (pentraxin 3 [PTX3], cellular fibrinogen [cFN], soluble tumor necrosis factor‐like weak inducer of apoptosis [sTWEAK]), and ATX. Additionally, the serum lipidomic biomarkers profile was also analyzed.

Results

Serum ATX levels were found to be significantly elevated in both patients with EM (mean [standard deviation, SD] 310.7 [79.7] ng/mL) and CM (mean [SD] 336.7 [66.9] ng/mL) compared to controls (mean [SD] 212.3 [53.2] ng/mL) ( p < 0.001). Elevated ATX levels were associated with migraine outcomes in CM, such as VAS score (Spearman's coefficient = 0.405, p < 0.05), frequency (Spearman's coefficient = 0.718, p < 0.001), and evolution time (Spearman's coefficient = 0.2257, p < 0.01). ATX was correlated with CGRP (Pearson's coefficient = 0.278, p < 0.001), PTX3 (Pearson's coefficient = 0.468, p < 0.001), sTWEAK (Pearson's coefficient = 0.242, p < 0.001), cFN (Pearson's coefficient = 0.252, p < 0.01), and IL‐6 serum levels (Pearson's coefficient = 0.159, p < 0.001). A drastic decrease in serum lysophosphatidylcholine levels indicates high ATX activity in patients with migraine.

Conclusions

Serum levels of ATX were significantly increased in patients with EM and CM. In addition, ATX correlates with clinical outcomes, as well as CGRP, endothelial dysfunction and inflammation biomarkers. Further studies are necessary to elucidate the potential role of ATX as a therapeutic target for migraine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphoric Diester HydrolasesMigraine DisordersHumansFemaleMaleAdultBiomarkersCross-Sectional StudiesMiddle AgedYoung AdultLysophospholipase D

Stichwörter der Autor:innen

autotaxincalcitonin gene‐related peptideendothelial dysfunctioninflammationlysophospholipidsmigraine

Substanzen

Phosphoric Diester HydrolasesBiomarkersLysophospholipase D

Autor:innen und Institutionen

  • NeuroAging Group Laboratory (NEURAL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
  • Centro de investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.
  • Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
  • Research Unit on BioActive Molecules, Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain.
  • Liver and Digestive Diseases Networking Biomedical Research Centre (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain.
  • Corneal Neurodegeneration Group (RENOIR), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.

ORCID-Profile: Alberto Ouro

Förderung

  • Xunta de Galicia
  • Interreg
  • Instituto de Salud Carlos III (ISCIII)
  • CIBERNED
  • Marie Skłodowska-Curie Actions - Postdoctoral Fellowship
  • European Regional Development Fund (ERDF)
  • Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas

Zitieren

APA

Ouro, A., Castro-Mosquera, M., Rodríguez-Arrizabalaga, M., Debasa-Mouce, M., Romaus-Sanjurjo, D., Aramburu-Nuñez, M., Iglesias-Rey, R., Casas, J., Lema, I., Castillo, J., Leira, R., & Sobrino, T. (2025). Serum levels of autotaxin reveal its role as a novel biomarker of migraine. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14922

Vancouver

Ouro A, Castro-Mosquera M, Rodríguez-Arrizabalaga M, Debasa-Mouce M, Romaus-Sanjurjo D, Aramburu-Nuñez M, et al. Serum levels of autotaxin reveal its role as a novel biomarker of migraine. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14922

BibTeX
@article{Ouro2025,
  author = {Ouro, Alberto and Castro-Mosquera, Mónica and Rodríguez-Arrizabalaga, Mariña and Debasa-Mouce, Manuel and Romaus-Sanjurjo, Daniel and Aramburu-Nuñez, Marta and Iglesias-Rey, Ramón and Casas, Josefina and Lema, Isabel and Castillo, José and Leira, Rogelio and Sobrino, Tomás},
  title = {Serum levels of autotaxin reveal its role as a novel biomarker of migraine},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  doi = {10.1111/head.14922}
}
Kostenlos starten →